DoorDash unit Deliveroo partners with Coco Robotics to launch UK robot deliveries
Bitget2026/10/05 12:10Deliveroo, part of DoorDash’s global portfolio, struck an exclusive UK partnership with Coco Robotics to scale sidewalk robot deliveries. Rollout starts in London’s Canary Wharf in October, then expands to Milton Keynes, Leeds, Stockton-on-Tees, Nottingham. Deal marks Deliveroo’s first use of autonomous delivery vehicles in the UK, adding short-distance capacity alongside its rider network. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DoorDash Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF63273) on October 05, 2026, and is solely responsible for the information contained therein.
- Deliveroo, part of DoorDash’s global portfolio, struck an exclusive UK partnership with Coco Robotics to scale sidewalk robot deliveries.
- Rollout starts in London’s Canary Wharf in October, then expands to Milton Keynes, Leeds, Stockton-on-Tees, Nottingham.
- Deal marks Deliveroo’s first use of autonomous delivery vehicles in the UK, adding short-distance capacity alongside its rider network.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Dollar Index falls to near 101.50 amid Fed rate pause odds, easing safe-haven demand
Utexo Mint open beta: Get early access to USD₮ on the bitcoin blockchain
"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%
Traders weighed the impact of Saudi attack risks and sharply reduced demand, causing oil prices to fall more than 2%.
JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential
Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.
Crypto prices
More
